Skip to main content

Table 2 Trial and Baseline Patient Characteristics, and Interventions of RCTs in Pericarditis, Post-Pericardiotomy Syndrome and Post-RF Ablation for Arrythmia

From: Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials

  Acute Pericarditis Acute Pericarditis First Re-current Pericarditis First Re-current Pericarditis Multiply Recurrent Pericarditis Post Pericardiotomy Syndrome Post Pericardiotomy Syndrome Post Pericardiotomy Syndrome Post Pericardiotomy Syndrome Post RF Ablation for Recurrent AFib
Colchicine Dose 0.25-0.5 mg bid (lower dose <70 kg or intolerance) 0.5 mg bid (daily ≤70 kg or intolerance) 0.25-0.5 mg bid (lower dose <70 kg or intolerance) 0.25-0.5 mg bid (lower dose <70 kg or intolerance) 0.5 mg bid (daily ≤70 kg or intolerance) 1.5 mg/d starting POD #3 0.5 mg bid (daily <70 kg) starting POD #3 with loading dose 0.5 mg bid (daily <70 kg) starting 48-72 h pre-op 0.5 mg bid 0.5 mg bid
Trial COPE (Imazio) 2005 [18] ICAP (Imazio) 2013 [19] CORE (Imazio) 2005 [20] CORP (Imazio) 2011 [21] CORP-2 (Imazio) 2014 [22 Finkelstein 2002 [23] COPPS (Imazio) 2010 [24] COPPS-2 (Imazio) 2014 [25] Sarzaeem 2014 [26] Deftereos 2012 [27]
N = 120 N = 240 N = 84 N = 120 N = 240 N = 163 N = 360 N = 360 N = 216 N = 230
Trial Characteristics           
No. Centres 2 5 1 4 4 2 6 11 1 3
Enrolment period Jan 2002 – Aug 2004 Aug 2005 – Dec 2010 Jan 2001 – Aug 2004 Aug 2005 – Apr 2009 Nov 2005 – Jan 2012 Oct 1997 – Sept 1998 n/r Mar 2012 – Mar 2014 Jan 2013 –Jul 2013 n/r
Treatment/ Follow Up 3 months/24 months (mean) 3 months/18 months (all)/ 22 months (mean) 6 months/20 months (mean) 6 months/ 18 months (all)/ 23 months (mean) 6 months/18 months (all)/ 20 months (mean) 1 month/3 months 1 month/19 months (mean) 1 month/3 months 7 days/Hosp discharge (mean 7 days) 3 months/15 (median) months
Funding Public Public Public Public Public n/r Public Public n/r n/r
Patients N = 120 N = 240 N = 84 N = 120 N = 240 N = 111 N = 360 N = 360 N = 216 N = 206
Mean Age (years) 57 52 54 48 49 64 66 68 60 62
% Male 45 % 60 % 35 % 53 % 50 % 73 % 67 % 69 % 72 % 70 %
BMI          26 26
Diabetes     3 %   27 % 23 % 22 % 37 % 25 %
HTN     23 %   46 % 68 % 68 % 53 % 41 %
Smoker     49 %   48 % 13 % 29 % 30 % 35 %
Dyslipidemia       42 %     
Prev MI/UA     11 % 7 % 40 % 21 %    34 % (CAD)
Prev stroke/TIA          2 %  
PVD           
CRD (Excl Cr >2.5 mg/dL/ 221 μM) (Excl Cr >2.5 mg/dL/ 221 μM) (Excl Cr >2.5 mg/dL/ 221 μM) 5 % (CrCl <60 mL/min; Excl Cr >2.5 mg/dL/ 221 μM) (Excl Cr >2.5 mg/dL/ 221 μM)   15 % (CrCl <60 mL/min; Excl Cr >2.5 mg/dL/ 221 μM) 7 % (Excl Cr >2.5 mg/dL/ 221 μM) Excl Excl eGFR <30 mL/min
Mean LVEF     58 %    54 % 55 % 47 % 55 %
Previous CABG     6 % 4 %   6 % 6 % Excl  
Medications           
ASA and/or clopidogrel   76 % (ASA)    76 % (ASA)      
Statin           37 %
Beta-Blocker           36 %
Calcium Channel Blocker           41 %
ACE Inhibitor           54 % (incl ARB)
Diuretic           
  1. Abbreviations: ACE angiotensin converting enzyme, ACS acute coronary syndrome, ARB angiotensin receptor blocker, AFib atrial fibrillation, ASA acetylsalicylic acid (aspirin), bid twice daily, BMI body mass index, BMS bare metal stent, CABG coronary artery bypass grafting, CAD coronary artery disease, CHF congestive heart failure, chol cholesterol, Cr serum creatinine concentration, CrCl creatinine clearance, CRD chronic renal disease, DAPT dual anti-platelet therapy, DM diabetes mellitus, dL deciliter, eGFR estimated glomerular filtration rate, excl excluded, h hour, HTN hypertension, kg kilogram (body weight), LVEF left ventricular ejective fraction, mg milligram, μM micromolar, MI myocardial infarction, mL milliliter, N number of patients, no. number, n/r not reported, PCI percutaneous coronary intervention, POD post-operative day, prev previous, PTCA percutaneous coronary angioplasty, PVD peripheral vascular disease, RF radiofrequency, TIA transient ischemic attack, UA unstable angina, yrs years